Metoclopramide for Gastric Visualization in Active Upper GI Bleeding

Launched by KING CHULALONGKORN MEMORIAL HOSPITAL · Dec 11, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called metoclopramide to improve the visibility of the stomach during an emergency procedure for patients experiencing active upper gastrointestinal bleeding (UGIB). If a patient has symptoms like vomiting blood or fresh blood found in a tube inserted into their stomach, they might be eligible for this study. To participate, individuals must be at least 18 years old and need to have the procedure scheduled within 12 hours of showing these bleeding symptoms. However, those with known allergies to metoclopramide, previous stomach surgeries, certain cancers, advanced HIV, pregnant individuals, or if a specific type of stomach wash was performed, cannot join.

Participants in the trial will be randomly assigned to receive either intravenous metoclopramide or a placebo (a treatment that has no active medication) before their endoscopy, a procedure used to look inside the stomach. The main goal of the study is to see if metoclopramide helps doctors get a clearer view of the stomach during the procedure. Other aspects being looked at include how long the procedure takes, whether immediate bleeding control is achieved, and the overall recovery process, including hospital stay and chances of rebleeding within 30 days. This study is currently recruiting participants, and it aims to ensure that those involved receive careful attention and care throughout the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All adult patients (aged ≥ 18years)
• • Active UGIB who arrived at emergency room (ER) and had a schedule for EGD within 12 hours after onset of bleeding ; Active UGIB was defined as having hematemesis or fresh blood by diagnostic gastric lavage at the ER.
• Exclusion Criteria:
• • known allergy to metoclopramide
• • prior gastric or duodenal surgery
• • known case of esophageal, gastric or duodenal cancer;
• • advanced HIV infection (defined as WHO criteria13-15: CD4 \<200 cell/mm3 or WHO clinical stage 3 or 4)
• • pregnancy
• • gastric lavage was performed with solution \> 50 ml.